Table 3. Characteristics of responders to second-line M-VAC regimen.
| No. | Age | Site of disease | Response to GC | Treatment-free interval (month) | Response to M-VAC | RD (month) | PFS (month) | Current status | Survival (month) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | Bone Supraclavicular LN | PR | 3.2 | PR | 6.6 | 8.6 | Death | 11.7 |
| 2 | 54 | Retroperitoneal LN | PR | 4.5 | PR | 3.3 | 6.4 | Death | 9.2 |
| 3 | 66 | Bladder Lung Retroperitoneal LN | PR | 5.7 | PR | 3.7 | 7.2 | Alive | 9.2+ |
| 4 | 72 | Lung Retroperitoneal LN | PR | 3 | PR | 3.9 | 7.6 | Death | 10.9 |
| 5 | 69 | Pelvic recurrence Lung Retroperitoneal LN | PR | 2 | PR | 3.8 | 7.1 | Death | 10.6 |
| 6 | 69 | Bladder Retroperitoneal LN | PD | 7 | CR | 1.5 | 4.4+ | Alive | 5.8+ |
| 7 | 64 | Retroperitoneal LN Carcinomatosis | CR | 1 | PR | 1.5 | 2.5+ | Alive | 5.3+ |
| 8 | 79 | Retroperitoneal LN | CR | 10.4 | CR | 7.2 | 10.6+ | Alive | 11.6+ |
| 9 | 52 | Bladder Scrotum | PD | 2.5 | PR | 3.9 | 6.7 | Death | 15.8 |
Abbreviations: CR=complete response; LN=lymph node; PD=progressive disease; PFS=progression-free survival; PR=partial response; RD=response duration.